Clinical significance of multidrug resistance and P-glycoprotein expression in patients with gastric carcinoma

✍ Scribed by Hidenori Fujii; Nobuhiko Tanigawa; Ryusuke Muraoka; Takumi Shimomatsuya; Takeo Tanaka

• Publisher: John Wiley and Sons
• Year: 1995
• Tongue: English
• Weight: 560 KB
• Volume: 58
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.2930580113

✦ Synopsis

Abstract

Twenty‐four fresh tumors of gastric carcinoma were assessed by flow cytometric detection of P‐glycoprotein (P‐gp) using monoclonal antibody C219. Eight patients were P‐gp positive. Differentiated gastric carcinomas contained significantly higher concentrations of P‐gp positive. Incidence of P‐gp positive was high in advanced stage. In 16 cases estimated chemosensitivity was test assessed by thymidine incorporation assay (TIA). Seven of nine multidrug‐resistant cases according to TIA were P‐gp positive and all of seven nonmultidrug resistant cases were P‐gp negative. Expression of P‐gp and multidrug resistance were closely correlated (P < 0.01). Also, in 89 patients with operable gastric carcinoma, the relation between in vitro chemosensitivity test (TIA) and their clinicopathologic features as well as their survival lengths were studied. Thirty‐one of 89 specimens from gastric carcinoma patients were multidrug resistant according to TIA. Patients in the multidrug‐resistant group had a significantly poorer cumulative survival rate than those who were not multidrug resistant (P < .05). The multivariate analysis showed that multidrug resistance is a useful indicator of prognosis (P < 0.1). We suggest that multidrug‐resistant cases or P‐gp‐positive cases of gastric carcinoma are highly malignant, and these determinations are clinically useful. © 1995 Wiley‐Liss, Inc.